BioNTech and Pfizer will start a clinical trial of a Covid-19 vaccine adapted to the BA.4 and BA.5 variants of Omicron this month, as the German biotech forecasts an increase in demand at the end of the year.
The company missed sales and earnings expectations in the second quarter after the European Commission renegotiated its Covid vaccine contract amid a glut of shots.
Second-quarter sales were €3.2bn, compared with the average analyst estimate for €4bn, and adjusted earnings per share were €6.87, below the consensus forecast for €7.27. Net profit in the period was €1.7bn.
您已閱讀17%（579字），剩余83%（2750字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。